--- title: InsightRX to Present Latest Research and Platform Enhancements at ASHP 2024 Midyear Conference description: InsightRX showcases advancements in precision dosing at ASHP 2024, highlighting new research, platform updates, and additional drug modules to help improve outcomes. image: https://blog.insight-rx.com/hubfs/Copy%20of%20MCM24%20Exhibitor%20IG.png --- [![InsightRX](https://blog.insight-rx.com/hubfs/insightrx_logo_white-teal.svg)](https://blog.insight-rx.com/) - For Providers - Solutions - [MIPD for Providers Explore our full solution for Bayesian model-informed dosing](https://www.insight-rx.com/mipd) - [Future of Pharmacy Learn what's next for AI in health tech, and why architecture matters](https://www.insight-rx.com/future) - Products - [InsightRX Nova Bayesian dosing (MIPD) app for bedside clinical decision support](https://www.insight-rx.com/provider/nova) - [InsightRX Apollo Real-time clinical analytics to measure outcomes](https://www.insight-rx.com/provider/apollo) - [Drug Modules Available medications for precision dosing apps](https://www.insight-rx.com/provider/drug-modules) - [For Life Sciences](https://www.insight-rx.com/life-sciences) - Overview - [InsightRX for Life Sciences Explore our solution for biopharma and clinical trial use](https://www.insight-rx.com/life-sciences) - Products - [Nova for Life Sciences Precision dosing app for clinical trial use](https://www.insight-rx.com/life-sciences/nova) - [Astra for Life Sciences AI-native environment for PK/PD modeling and simulation](https://www.insight-rx.com/life-sciences/astra) - Platform - [Continuous Learning Patented process for model retraining and improvement](https://www.insight-rx.com/platform/continuous-learning) - [Integrations Platform interoperability setup with EHRs, EDCs, and more](https://www.insight-rx.com/platform/integrations) - [Security & Regulatory Standards for product development and release](https://www.insight-rx.com/platform/security-regulatory) - [Success & Support Pharmacist-led training, onboarding, and education](https://www.insight-rx.com/platform/support) - Resources - Science - [Data Science Explore the science and learn more about our R&D](https://www.insight-rx.com/data-science) - [Scientific Publications Impactful research manuscripts with at least one InsightRX author](https://www.insight-rx.com/data-science/scientific-publications) - [How to Cite Using one of our apps? Follow this easy guide for citation in research](https://www.insight-rx.com/how-to-cite-insightrx-nova) - Explore - [Success Stories Case studies from real InsightRX customers about their journey](https://www.insight-rx.com/success-stories) - [White Papers In-depth analysis and best practices for review and download](https://blog.insight-rx.com/resources/tag/white-papers) - [Pubs. Using InsightRX Review research that has used InsightRX applications](https://www.insight-rx.com/publications-using-insightrx-software) - [Blog](https://blog.insight-rx.com/resources) - [All Blog Posts Read the latest posts by our team of experts](https://blog.insight-rx.com/resources) - [Product Innovation The latest updates on our products, services, and science](https://blog.insight-rx.com/resources?section=product_innovation) - [Thought Leadership Posts from our team of experts on PK, MIPD, science, and more](https://blog.insight-rx.com/resources?section=thought_leadership) - Company - About - [About Us Our story, what drives us and why we're passionate about our work](https://www.insight-rx.com/about) - [Leadership Founders and team leaders who strive toward excellence in MIPD](https://www.insight-rx.com/leadership) - [Advisory Board Scientists and experts to ensure our collective success](https://www.insight-rx.com/advisory-board) - [Careers Interested in joining? View available openings here](https://www.insight-rx.com/careers) - [Customers Hear what others have to say about their experience](https://www.insight-rx.com/customers) - Press - [All Stories InsightRX news, company updates, and more](https://blog.insight-rx.com/press-releases) - [Press Releases Announcements for events, partnerships, and company updates](https://blog.insight-rx.com/press-releases?section=press_releases) - [Media InsightRX in the news — digital, print, podcasts, and other outlets](https://blog.insight-rx.com/press-releases?section=media) [![Contact Us](https://no-cache.hubspot.com/cta/default/40041574/interactive-193831493462.png)](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574) [![Contact Us](https://no-cache.hubspot.com/cta/default/40041574/interactive-193831493462.png)](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574) Press Releases # InsightRX to Present Latest Research and Platform Enhancements at ASHP 2024 Midyear Conference - Published December 3, 2024 By [InsightRX Communications](https://blog.insight-rx.com/press-releases/author/insightrx) ![](https://blog.insight-rx.com/hubfs/Copy%20of%20MCM24%20Exhibitor%20IG.png) **SAN FRANCISCO, December 3, 2024** – InsightRX – the leader in Bayesian model-informed precision dosing (MIPD) software – today announced it will attend the ASHP 2024 Midyear Clinical Meeting & Exhibition as both an exhibitor and presenter. The meeting is scheduled for Dec 8-12 at the Ernest N. Morial Convention Center in New Orleans. ASHP 2024 is organized by the American Society of Health-System Pharmacists and will include vendor exhibits, educational sessions, poster presentations, and networking opportunities for pharmacy professionals. Representatives from the InsightRX team will be at **booth 1340 in the exhibition hall** to meet with visitors and discuss product updates, new features, and benefits of Bayesian MIPD adoption: **Exhibition Hall Booth 1340** Monday, Dec 9 from **11am - 3pm** Tuesday, Dec 10 from **11am - 3pm** Wednesday, Dec 11 from **11am - 2pm** Additionally, InsightRX Senior Director of Product & Customer Experience Jonathan Faldasz, PharmD, BCPS, will present a poster from the InsightRX team: **Poster Presentation Title:** Proposed Update to the Cockcroft-Gault Equation for Patients with Low Serum Creatinine: Results from a Massive Multi-Site Dataset **Date and Time:** Monday, Dec 9 from 2pm - 3:30pm **Session-Board Number:** 4-016 **Submission ID#:** 1857562 This study evaluated the accuracy of the Cockcroft-Gault equation–long regarded as the gold standard for estimating renal function–in patients with serum creatinine levels below 1 mg/dL. By analyzing data from nearly 100,000 patients, the InsightRX team identified significant inaccuracies in the equation's predictions for this population. In response, they developed a modified equation incorporating adjusted serum creatinine, which demonstrated greatly improved accuracy. The poster will detail these findings and their implications for clinical practice. Front and center will be demonstrations of a [new feature to the Nova platform](https://blog.insight-rx.com/press-releases/insightrx-gemini-model-selection-algorithm-release), InsightRX Gemini, designed to eliminate complexities of manual PK model selection. [InsightRX Gemini automatically chooses the best-performing PK model for the patient](https://blog.insight-rx.com/resources/introduction-to-insightrx-gemini-patient-model-selection), based on four common covariates, and was built analyzing approximately 400,000 vancomycin treatment courses contained in the Nova data lake. When compared to commonly available PK models (seen in “freeware” and various other applications), InsightRX Gemini: - Increases dosing accuracy for individual patients up to **47.2%** - Increases precision by up to **25%** - Decreases bias by up to **93%** Overall, MIPD dosing activities have increased for a variety of therapeutic areas and hold promise for enhancing workflows and producing more accurate dosing and improved outcomes. In addition to vancomycin, InsightRX offers numerous other Drug Modules, which the team will also present at the exhibition. Several of these were highlighted in recent studies, thought leadership articles, and blog posts by the InsightRX team over the past year, including: - [Antifungals](https://blog.insight-rx.com/resources/personalized-antifungal-therapy-precision-dosing-posaconazole) – Posaconazole is a pharmacotherapeutic pillar for prophylaxis and treatment of invasive fungal diseases. Dose individualization is critical to achieving adequate antifungal exposure associated with improved outcome. InsightRX validated an MIPD strategy for posaconazole for its fit-for-purpose, an important first step toward dosage optimization with the goal to improve antifungal treatment in clinical practice. - [Beta-lactams](https://blog.insight-rx.com/resources/overcoming-barriers-beta-lactam-tdm-bayesian-dosing) – Therapeutic drug monitoring (TDM) can improve PK/PD target attainment of beta-lactam levels and optimize dosing in vulnerable populations. There are still several barriers to widespread adoption of TDM of beta-lactams into routine clinical practice, however, beta-lactam TDM has great potential to improve patient care by optimizing antibiotic dosing, especially in high-risk populations. - [Solid organ transplant](https://blog.insight-rx.com/resources/evolution-therapeutic-drug-monitoring-tacrolimus) – Therapeutic drug monitoring is essential with tacrolimus, one of the key immunosuppressive agents used after solid organ transplant. Although most transplant centers rely on trough concentrations drawn immediately before the dose, evidence shows a poor correlation between tacrolimus trough concentrations and outcomes. A 2019 tacrolimus guidance document concludes that Bayesian estimation may be a better way to improve future tacrolimus TDM. - [Bone marrow transplant](https://blog.insight-rx.com/resources/bayesian-outperforms-nca-busulfan-dosing) – Dose personalization improves patient outcomes for many drugs with a narrow therapeutic index and high inter-individuality variability, including busulfan. In a simulated study, InsightRX demonstrated that while area under the curve (AUC) estimates between the two methods showed good correlation, the maximum a posteriori Bayesian (MAP) approach led to higher target attainment for busulfan dosing. - [Anticoagulants](https://blog.insight-rx.com/resources/heparin-dosing-pharmacokinetics-mipd) – Heparin is a lifesaving mainstay of anticoagulation in patients at high risk of coagulation-related morbidity and mortality. Yet most hospitals struggle to keep their patients at a target heparin exposure, which can result in increased morbidity and mortality from both clotting and bleeding events. Several exciting advances in the use of MIPD for heparin would allow clinicians to better individualize therapy for each treatment course. - [Inflammatory bowel disease](https://blog.insight-rx.com/resources/infliximab-pk-model-performance-dutch-ibd) – Efficacy of infliximab in children with inflammatory bowel disease can be enhanced when serum concentrations are measured and further dosing is adjusted to achieve and maintain a target concentration. A recent collaborative study showed that a population pharmacokinetic model may help to predict an individual's infliximab dose requirement. > "InsightRX has enjoyed a year of real growth and accomplishment and we’re excited to meet with our colleagues at ASHP in New Orleans to discuss what we’ve learned and how we plan to continue improving dosing safety and accuracy,” said Sirj Goswami, PhD, CEO and cofounder of InsightRX. > > “Model-informed precision dosing holds great promise for contributing to better clinical outcomes and operational efficiency." --- **About ASHP Midyear** The [ASHP Midyear Clinical Meeting & Exhibition](https://midyear.ashp.org/) is the largest gathering of pharmacy professionals worldwide, focusing on advancing pharmacy practice and patient care through education, networking, and innovation. Attracting over 20,000 attendees annually, the conference features sessions on clinical updates, leadership development, and practice trends, alongside an extensive exhibit hall showcasing the latest in pharmacy products and services. **Media Contact** Michelle Noteboom Amendola Communications for InsightRX [mnoteboom@acmarketingpr.com](mailto:mnoteboom@acmarketingpr.com) [antifungals](https://blog.insight-rx.com/press-releases/tag/antifungals) [insightrx gemini](https://blog.insight-rx.com/press-releases/tag/insightrx-gemini) [conferences](https://blog.insight-rx.com/press-releases/tag/conferences) [ASHP](https://blog.insight-rx.com/press-releases/tag/ashp) [beta-lactams](https://blog.insight-rx.com/press-releases/tag/beta-lactams) [heparin](https://blog.insight-rx.com/press-releases/tag/heparin) [infliximab](https://blog.insight-rx.com/press-releases/tag/infliximab) #### On this page… **Connect with us to get the latest blog updates, instantly sent to your inbox** ## Dig deeper. Explore related articles and additional posts on the InsightRX blog. [Press Releases Nov 28, 2023 InsightRX Brings Groundbreaking Advancements in Model-Informed Precision Dosing to the ASHP Midyear Conference](https://blog.insight-rx.com/press-releases/insightrx-brings-groundbreaking-advancements-model-informed-precision-dosing-ashp-midyear-conference) [Press Releases Jul 30, 2020 New Study Co-Authored By InsightRX Shows Model-Informed Precision Dosing Could Improve Efficacy Of Hematopoietic Cell Transplants While Reducing Toxicity](https://blog.insight-rx.com/press-releases/model-informed-precision-dosing-hematopoietic-cell-transplants-reducing-toxicity) [Press Releases Jul 25, 2022 InsightRX Precision Medicine Software Platform Selected by Amsterdam UMC](https://blog.insight-rx.com/press-releases/insightrx-precision-medicine-software-platform-selected-amsterdam-umc) #### What We Do ##### For Providers - [Nova (Bayesian Dosing)](https://www.insight-rx.com/provider/nova) - [Apollo (Clinical Analytics)](https://www.insight-rx.com/provider/apollo) - [Drug Modules](https://www.insight-rx.com/provider/drug-modules) ##### For Life Sciences - [Nova (MIPD for Clinical Trials)](https://www.insight-rx.com/life-sciences/nova) - [Astra (AI-Powered Clin Pharm)](https://www.insight-rx.com/life-sciences/astra) - [Companion Applications](https://www.insight-rx.com/life-sciences/nova#companion-applications) #### How We Do It ##### Platform - [Continuous Learning](https://www.insight-rx.com/platform/continuous-learning) - [Integrations](https://www.insight-rx.com/platform/integrations) - [Security & Regulatory](https://www.insight-rx.com/platform/security-regulatory) - [Success & Support](https://www.insight-rx.com/platform/success-support) ##### Science - [Data Science](https://www.insight-rx.com/data-science) - [Scientific Publications](https://www.insight-rx.com/data-science/scientific-publications) #### Information ##### Resources - [Success Stories](https://www.insight-rx.com/success-stories) - [White Papers](https://www.insight-rx.com/white-papers) - [Publications Using InsightRX](https://www.insight-rx.com/publications-using-insightrx-software) - [How to Cite InsightRX](https://www.insight-rx.com/how-to-cite-insightrx-nova) ##### Blog - [All Posts](https://blog.insight-rx.com/resources) - [Product Innovation](https://blog.insight-rx.com/resources?section=product_innovation) - [Thought Leadership](https://blog.insight-rx.com/resources?section=thought_leadership) #### About - [Our Story](https://www.insight-rx.com/about) - [Leadership](https://www.insight-rx.com/leadership) - [Advisory Board](https://www.insight-rx.com/advisory-board) - [Our Customers](https://www.insight-rx.com/customers) - [Press Releases](https://blog.insight-rx.com/press-releases?section=press_releases) - [Media](https://blog.insight-rx.com/press-releases?section=media) - [Careers](https://www.insight-rx.com/careers) - [Contact](https://www.insight-rx.com/contact-us) --- ![CE marking](https://blog.insight-rx.com/hubfs/ce-mark-white.svg) InsightRX Nova is HITRUST CSF r2 certified, CE marked, and 21 CFR Part 11 compliant. Our quality management, risk management, software lifecycle, and usability engineering processes conform to ISO 13485, IEC 62304, ISO 14971, IEC 62366-1, and IEC 82304-1. InsightRX Nova is not considered to be a medical device in the U.S. and has not been submitted to the U.S. Food and Drug Administration for review or clearance. 740-05000-REC-01 · 08/2025 --- [![InsightRX](https://blog.insight-rx.com/hubfs/insightrx_logo_white-teal.svg)](https://www.insight-rx.com/) 548 Market Street #88083 San Francisco, CA 94104 --- © 2026 InsightRX, Inc. All rights reserved. [Privacy Policy](https://www.insight-rx.com/privacy-policy) Cookie Preferences ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "InsightRX Communications", "url" : "https://blog.insight-rx.com/press-releases/author/insightrx" }, "dateModified" : "2025-12-13T02:43:13.319Z", "datePublished" : "2024-12-03T14:51:00.000Z", "headline" : "InsightRX to Present Latest Research and Platform Enhancements at ASHP 2024 Midyear Conference", "image" : [ "https://blog.insight-rx.com/hubfs/Copy%20of%20MCM24%20Exhibitor%20IG.png" ], "mainEntityOfPage" : { "@id" : "https://blog.insight-rx.com/press-releases/ashp-midyear-2024-insightrx-exhibit-presentation", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.insight-rx.com/hubfs/insightrx_logo_color%20500%20x%20250-1.png" }, "name" : "InsightRX" } } ```